Ligand Pharma Highlights Broad Disclosure of Athira Investment

The latest update is out from Ligand Pharma ( (LGND) ).

On December 18, 2025, Ligand Pharmaceuticals disclosed that it had posted materials related to its private placement investment in Athira Pharma on its investor relations website and certain social media platforms. The company reiterated that it distributes potentially material information through a broad set of public channels, including SEC filings, its website, press releases, conference calls, webcasts and its social media accounts, and urged investors and other stakeholders to monitor these outlets for updates, underscoring its emphasis on wide, non-exclusionary disclosure in line with regulatory requirements.

The most recent analyst rating on (LGND) stock is a Buy with a $231.00 price target. To see the full list of analyst forecasts on Ligand Pharma stock, see the LGND Stock Forecast page.

Spark’s Take on LGND Stock

According to Spark, TipRanks’ AI Analyst, LGND is a Neutral.

Ligand Pharma’s overall stock score reflects a mix of strong earnings call performance and stable financial structure, offset by bearish technical indicators and high valuation concerns. The company’s ability to manage cash flow and improve operational efficiency will be crucial for future performance.

To see Spark’s full report on LGND stock, click here.

More about Ligand Pharma

Ligand Pharmaceuticals is a biopharmaceutical company that generates revenue primarily through a portfolio of drug royalties, partnerships and investments, focusing on developing and acquiring technologies and assets that enable pharmaceutical innovation across multiple therapeutic areas.

Average Trading Volume: 200,383

Technical Sentiment Signal: Buy

Current Market Cap: $3.79B

See more data about LGND stock on TipRanks’ Stock Analysis page.